NO20060374L - Peptider og peptidomimetiks med immun-modulerende, anti-inflammatorisk og anti-viral aktivitet - Google Patents
Peptider og peptidomimetiks med immun-modulerende, anti-inflammatorisk og anti-viral aktivitetInfo
- Publication number
- NO20060374L NO20060374L NO20060374A NO20060374A NO20060374L NO 20060374 L NO20060374 L NO 20060374L NO 20060374 A NO20060374 A NO 20060374A NO 20060374 A NO20060374 A NO 20060374A NO 20060374 L NO20060374 L NO 20060374L
- Authority
- NO
- Norway
- Prior art keywords
- immunomodulatory
- inflammatory
- peptidomimetics
- peptides
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48275003P | 2003-06-25 | 2003-06-25 | |
PCT/IB2004/002591 WO2004112820A2 (fr) | 2003-06-25 | 2004-06-25 | Peptides et peptidomimetiques activite immunomodulatrice, anti-inflammatoire et antivirale |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20060374L true NO20060374L (no) | 2006-03-20 |
Family
ID=33539355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20060374A NO20060374L (no) | 2003-06-25 | 2006-01-24 | Peptider og peptidomimetiks med immun-modulerende, anti-inflammatorisk og anti-viral aktivitet |
Country Status (10)
Country | Link |
---|---|
US (2) | US7479484B2 (fr) |
EP (1) | EP1648490A2 (fr) |
JP (1) | JP4705567B2 (fr) |
KR (1) | KR20060065588A (fr) |
CN (1) | CN1812805A (fr) |
AU (1) | AU2004248998A1 (fr) |
CA (1) | CA2530900A1 (fr) |
NO (1) | NO20060374L (fr) |
WO (1) | WO2004112820A2 (fr) |
ZA (1) | ZA200510341B (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4705567B2 (ja) * | 2003-06-25 | 2011-06-22 | 株式会社 キャンバス | 免疫調整活性、抗炎症活性、および抗ウイルス活性を有するペプチドおよびペプチド模倣物 |
US20100298329A1 (en) * | 2007-09-19 | 2010-11-25 | Massachusette Institute Of Technology | Tolperisone and tolperisone-like drugs for the treatment of k-ras associated cancers |
KR102578891B1 (ko) | 2012-05-11 | 2023-09-15 | 주식회사 젬백스앤카엘 | 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물 |
EP2873678B1 (fr) | 2012-07-11 | 2024-06-26 | Gemvax & Kael Co.,Ltd | Conjugué comprenant une peptide de pénétration cellulaire, et composition le comprenant |
CA2912557A1 (fr) | 2013-06-07 | 2014-12-11 | Gemvax & Kael Co., Ltd. | Marqueurs biologiques utiles en immunotherapie du cancer |
ES2808076T3 (es) | 2013-06-21 | 2021-02-25 | Gemvax & Kael Co Ltd | Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso |
AU2014300713B2 (en) * | 2013-06-24 | 2019-02-14 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations |
WO2015076621A1 (fr) | 2013-11-22 | 2015-05-28 | 주식회사 카엘젬백스 | Peptide ayant une activité d'inhibition d'angiogenèse, et composition le contenant |
EP3085380B1 (fr) | 2013-12-17 | 2020-06-17 | Gemvax & Kael Co., Ltd. | Composition pour traiter un cancer de la prostate |
ES2962532T3 (es) | 2014-04-30 | 2024-03-19 | Gemvax & Kael Co Ltd | Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante |
WO2015178508A1 (fr) * | 2014-05-22 | 2015-11-26 | Canbas Co., Ltd. | Traitement anticancéreux à base de nrf2 et procédés de détection et utilisations |
KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
ES2799511T3 (es) | 2015-02-27 | 2020-12-18 | Gemvax & Kael Co Ltd | Péptido para prevenir la pérdida de audición, y composición que lo comprende |
KR102638286B1 (ko) | 2015-07-02 | 2024-02-20 | 주식회사 젬백스앤카엘 | 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물 |
CN117018162A (zh) | 2016-04-07 | 2023-11-10 | 珍白斯凯尔有限公司 | 具有增加端粒酶活性和延长端粒的效果的肽以及组合物 |
CN108484745B (zh) * | 2018-05-17 | 2021-06-25 | 青岛大学 | 一种小麦白粉病抗性相关蛋白TaSARD1及其编码基因与应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6239268B1 (en) * | 1994-09-09 | 2001-05-29 | Neurocrine Biosciences, Inc. | Interleukin-1 type 3 receptors |
CA2216559A1 (fr) * | 1997-09-25 | 1999-03-25 | Michel Roberge | Inhibiteurs du point de controle g2 et dosage |
US6881575B1 (en) * | 1999-09-22 | 2005-04-19 | Canbas Co., Ltd. | Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents |
US6495586B2 (en) * | 2000-02-25 | 2002-12-17 | The Regents Of The University Of California | Scytonemin and methods of using thereof |
DK1483290T3 (da) * | 2002-01-17 | 2008-11-03 | Takeda Pharmaceutical | Peptider og peptidmimetika, der har anti-proliferativ aktivitet og/eller forstærker nukleinsyrebeskadigende midler eller behandlinger |
US7125842B2 (en) * | 2003-04-07 | 2006-10-24 | Canbas Co. Ltd. | Anti-fungal compounds and methods of use |
JP4705567B2 (ja) * | 2003-06-25 | 2011-06-22 | 株式会社 キャンバス | 免疫調整活性、抗炎症活性、および抗ウイルス活性を有するペプチドおよびペプチド模倣物 |
-
2004
- 2004-06-25 JP JP2006516613A patent/JP4705567B2/ja not_active Expired - Lifetime
- 2004-06-25 US US10/877,961 patent/US7479484B2/en active Active
- 2004-06-25 EP EP04744226A patent/EP1648490A2/fr not_active Withdrawn
- 2004-06-25 AU AU2004248998A patent/AU2004248998A1/en not_active Abandoned
- 2004-06-25 KR KR1020057024882A patent/KR20060065588A/ko not_active Application Discontinuation
- 2004-06-25 CA CA002530900A patent/CA2530900A1/fr not_active Abandoned
- 2004-06-25 CN CNA2004800180028A patent/CN1812805A/zh active Pending
- 2004-06-25 WO PCT/IB2004/002591 patent/WO2004112820A2/fr active Application Filing
-
2005
- 2005-12-20 ZA ZA200510341A patent/ZA200510341B/en unknown
-
2006
- 2006-01-24 NO NO20060374A patent/NO20060374L/no not_active Application Discontinuation
-
2008
- 2008-12-31 US US12/347,683 patent/US20090192090A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2007521256A (ja) | 2007-08-02 |
AU2004248998A1 (en) | 2004-12-29 |
ZA200510341B (en) | 2007-05-30 |
US20090192090A1 (en) | 2009-07-30 |
US7479484B2 (en) | 2009-01-20 |
WO2004112820A2 (fr) | 2004-12-29 |
JP4705567B2 (ja) | 2011-06-22 |
KR20060065588A (ko) | 2006-06-14 |
US20060003941A1 (en) | 2006-01-05 |
CN1812805A (zh) | 2006-08-02 |
EP1648490A2 (fr) | 2006-04-26 |
CA2530900A1 (fr) | 2004-12-29 |
WO2004112820A3 (fr) | 2005-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20060374L (no) | Peptider og peptidomimetiks med immun-modulerende, anti-inflammatorisk og anti-viral aktivitet | |
Tamamura et al. | Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes | |
WO2003087768A3 (fr) | Cibles pour une intervention therapeutique identifiee dans le proteome mitochondrial | |
ATE382364T1 (de) | Von igf-bindungsprotein stammendes peptid | |
DE60045030D1 (de) | Peptid yy (pyy) zur behandlung von glukose stoffwechselkrankheiten | |
AR021876A1 (es) | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado | |
ATE539744T1 (de) | Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem | |
DE69434181D1 (de) | Therapeutische Peptid Derivate | |
DK1483290T3 (da) | Peptider og peptidmimetika, der har anti-proliferativ aktivitet og/eller forstærker nukleinsyrebeskadigende midler eller behandlinger | |
IL204453A (en) | Use of human magic roundabout (mr), for the preparation of drugs to inhibit migration and / or proliferation of endothelial cells | |
AR045870A1 (es) | Terapia de combinacion para la infeccion de virus de hepatitis c | |
DK1476468T3 (da) | Fab-fragmenter af humant monoklonalt antistof rettet mod HCV E2-glycoprotein og med in vitro-neutraliserende aktivitet | |
ES2530670T3 (es) | Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo | |
DK1641820T3 (da) | Fra RasGap afledt peptid til selektiv at dræbe kræftceller | |
DE50205029D1 (de) | Entzündungsspezifische peptide und deren verwendungen | |
EA200500871A1 (ru) | Пептиды, ингибирующие ангиогенез, миграцию клеток, инвазию клеток и пролиферацию клеток, композиции и их применение | |
DE602005010844D1 (de) | Pharmazeutische zusammensetzungen mit interferon-tau | |
ATE484290T1 (de) | Peptid mit antitumoraler wirkung | |
ATE521624T1 (de) | Peptide und medizinische zusammensetzungen mit denselben | |
ATE410448T1 (de) | Neues peptid und pharmazeutische zusammensetzung, die dieses peptid enthält | |
DE69011122D1 (de) | Rubella-e1 und c peptide. | |
ATE384078T1 (de) | Paralytisches peptide von der spitzmaus sowie dessen nutzung in der therapie von neuromuskulären krankheiten | |
TR199902866T2 (xx) | Organo- koruyucu aktiviteye sahip yeni BPC peptid tuzlar�, haz�rlanmalar� ve terapide kullan�lmalar� i�in prosesler. | |
DE69738600D1 (de) | Neuroaktive peptide | |
WO2003072606A3 (fr) | Agents de liaison de glycoproteines cd44 et methodes d'utilisation associees |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |